Enveric Biosciences Announces Participation in 2026 BIO International Convention

About this update from Enveric Biosciences, Inc.

CAMBRIDGE, Mass., June 16, 2026--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 22-25, 2026, in San Diego, California. "We are arriving at BIO with strong operational momentum, driven by the recently announced positive preclinical phototoxicity results and the initiation of IND-enabling GLP genotoxicity studies for EB-003," said Joseph Tucker, Ph.D., CEO of Enveric Biosciences. "This milestone moves us steadily toward IND submission and Phase 1 clinical entry. We are looking forward to meeting with potential strategic partners at the convention to discuss our continued progress and the unique mechanism of EB-003." Members of the Enveric management team will host meetings throughout the convention. Registered attendees can request a meeting using the BIO One-on-One PartneringTM platform. About Enveric Biosciences Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT2A and 5-HT1B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience. For more information, please visit www.enveric.com. Forward-Looking Statements This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "propos...

View stock analysis, news, and events for Enveric Biosciences, Inc.